Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneus Ltd. (AU:CMB)
ASX:CMB
Holding AU:CMB?
Track your performance easily
CMB Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.30 - AU$1.60
Previous CloseAU$0.4
Volume1.04K
Average Volume (3M)1.81K
Market Cap
AU$4.71M
Enterprise ValueAU$5.56M
Total Cash (Recent Filing)AU$164.40K
Total Debt (Recent Filing)AU$1.01M
Price to Earnings (P/E)―
Beta-7.01
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares OutstandingN/A
10 Day Avg. Volume1,426
30 Day Avg. Volume1,814
Standard Deviation0.22
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)16.04
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Regeneus Ltd. News
PremiumCompany Announcements
Cambium Bio Revises CEO Compensation Agreement
PremiumCompany Announcements
Cambium Bio Reports Mixed Annual Results
PremiumCompany Announcements
Apex Metro’s Voting Power Diluted in Cambium Bio
PremiumCompany Announcements
Treasure Century’s Voting Power Diluted in Cambium Bio
PremiumCompany Announcements
Cambium Bio Advances Toward Pivotal Trials
PremiumCompany Announcements
Cambium Bio Limited’s Stake in Regeneus Diluted
PremiumCompany Announcements
Regeneus Ltd Finalizes Share Consolidation
PremiumCompany Announcements
Cambium Bio Announces Cessation of 3.8M SecuritiesCMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.30 and its highest was AU$1.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Currently, no data Available
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Feb 27, 2025 which is in 160 days.
How were Regeneus Ltd.’s earnings last quarter?
Currently, no data Available
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 11,931,006 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
---
Regeneus Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:CMB Sentiment 50%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth AU$1.2M over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-469.28%
Trailing 12-Months
Asset Growth
690.69%
Trailing 12-Months
Company Description
Regeneus Ltd.
Regeneus Ltd clinical-stage regenerative medicine company. It mainly develops a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing.
---
Technical Analysis
PYC Therapeutics Limited
―
Race Oncology Ltd.
―
Botanix Pharmaceuticals Limited
―
Cryosite Limited
―
---